Header Logo

Connection

SUSAN HILSENBECK to Treatment Outcome

Back to Details
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Treatment Outcome.
SUSAN HILSENBECK
Connection Strength
0.322
Treatment Outcome
  1. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.021
  2. Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer. Endocr Relat Cancer. 2025 Jun 01; 32(6).
    View in: PubMed
    Score: 0.020
  3. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
    View in: PubMed
    Score: 0.018
  4. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
    View in: PubMed
    Score: 0.014
  5. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.014
  6. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
    View in: PubMed
    Score: 0.013
  7. Measure once or twice -- does it really matter? J Natl Cancer Inst. 1999 Mar 17; 91(6):494-5.
    View in: PubMed
    Score: 0.013
  8. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
    View in: PubMed
    Score: 0.012
  9. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
    View in: PubMed
    Score: 0.011
  10. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.
    View in: PubMed
    Score: 0.011
  11. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
    View in: PubMed
    Score: 0.010
  12. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.010
  13. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51.
    View in: PubMed
    Score: 0.009
  14. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.009
  15. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11.
    View in: PubMed
    Score: 0.008
  16. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.
    View in: PubMed
    Score: 0.008
  17. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43.
    View in: PubMed
    Score: 0.008
  18. Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.
    View in: PubMed
    Score: 0.008
  19. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
    View in: PubMed
    Score: 0.008
  20. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
    View in: PubMed
    Score: 0.007
  21. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
    View in: PubMed
    Score: 0.007
  22. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
    View in: PubMed
    Score: 0.007
  23. Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
    View in: PubMed
    Score: 0.006
  24. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.
    View in: PubMed
    Score: 0.006
  25. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.
    View in: PubMed
    Score: 0.006
  26. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
    View in: PubMed
    Score: 0.006
  27. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.
    View in: PubMed
    Score: 0.006
  28. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.005
  29. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.005
  30. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.005
  31. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.
    View in: PubMed
    Score: 0.005
  32. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
    View in: PubMed
    Score: 0.004
  33. Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
    View in: PubMed
    Score: 0.004
  34. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
    View in: PubMed
    Score: 0.004
  35. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.
    View in: PubMed
    Score: 0.004
  36. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11.
    View in: PubMed
    Score: 0.003
  37. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.
    View in: PubMed
    Score: 0.003
  38. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35.
    View in: PubMed
    Score: 0.003
  39. Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.